Top 5 Safest Stocks To Buy Right Now

Chipotle (NYSE:CMG) is now one of the major focuses of activist investor Bill Ackman after Pershing Square dumped its Valeant Pharmaceuticals (NYSE:VRX) stake. Ackman showed he has the patience to wait out a turnaround, as exhibited with VRX.

However, Ackman is cleaning up his portfolio. He’s also positioned himself, per an SEC filing in March, to be able to sell his near 3 million stake from time to time without having to file multiple registration statements.

Yet, CMG has started to regain strength. The stock is up 25% in 2017. This could give Ackman the encouragement to ride this out. Pershing’s average cost is right around $415 a share.

Top 5 Safest Stocks To Buy Right Now: Inc.(NTES)

Advisors’ Opinion:

  • [By Sreekanth Anasa]

    Shares of Hangzhou, China-based NetEase Inc (NASDAQ:NTES)popped 14% in the Feb 16th trading session after the company reported stellar Q4 and full-year 2016 earnings on Feb 15th after market close. The Chinese online gaming giant delivered an EPS of $4.30 on revenues of $1.74B beating EPS estimates by $0.86 and revenue estimates by $16oM. NetEase’s revenue grew by an impressive 53.1% YoY for Q4 and 67.7% for the full year 2016. On the back of these strong numbers, NTES stock closed at an all-time high of $298.73 in yesterday’s trading session. NTES stock might have gone up very high too soon. There could be a correction around the corner but still NTES stock is a great long-term proposition with much more upside left. Here’s why.

  • [By Joe Tenebruso]

    Shares ofNetEase (NASDAQ:NTES)popped 20.1% last month, according to data provided byS&P Global Market Intelligence, as the Chinese internet technology company’s strong fourth-quarter earnings report was applauded by investors.

Top 5 Safest Stocks To Buy Right Now: Eli Lilly and Company(LLY)

Advisors’ Opinion:


    Bond prices were much lower early in the day, with yields up by nearly 10 basis points. But fixed income has rallied back (reducing the drop by half on the day). Valeant Pharmaceuticals (VRX) , more weakness. Large pharma lower, led by Eli Lilly (LLY) . Old tech lags, with International Business Machines (IBM) , Intel (INTC) , Cisco Systems (CSCO) and Microsoft (MSFT) all lower. Media roughed up a bit (CBS (CBS) and Comcast (CMCSA) ). The Ugly
    Gold down another $23 to $1,188 (SPDR Gold Trust ETF (GLD) down $2.25). Urban Outfitters (URBN) down $5. NOTE: There will be no “Takeaways” today!   Happy Thanksgiving. Position: Long GLD small, SDS large, JCP large; short SPY, CSCO, CAT small, IWM, TLT small.


    That’s why Cramer said he’d use today’s weakness to buy Merck (MRK) , Eli Lilly (LLY) , Pfizer (PFE) and Allergan (AGN) , an Action Alerts PLUS holding.

  • [By Chris Lange]

    Eli Lilly & Co. (NYSE: LLY) saw its shares in free fall on Wednesday, not from the usual rhetoric of politicians or even the election, for that matter, but a late-stage trial failure. As 24/7 Wall St. has said time and again, clinical trials can make or break biotech and pharma companies. In this case Eli Lilly hit new 52-week lows, not seen since 2014 and this will not be a loss that Eli Lilly will easily forget. Effectively, the company announced results from its Phase 3 solanezumab trial in people with mild dementia due to Alzheimers disease (AD).

  • [By Johanna Bennett]

    Eli Lilly & Co. (LLY) and Biogen (BIIB) are far from the only two drug makers racing to deliver a new treatment for Alzheimers disease. But they are pretty much leading the pack.

    The market for an effective therapy that actually slows the progression of the disease would likely generate billions of dollars in annual sales. It is quite literally the drug industrys version of the holy grail.

    And according to Barclays analysts Geoff Meacham and Paul Choi, the next few weeks could prove to be one of the most fertile periods in Alzheimers disease research since 2008.

    We think the most likely outcome for Lilly’s Phase 3 EXPEDITION 3 (E3) solanezumab trial is the primary cognition (ADAS-Cog14) endpoint is met (just achieving statistical significance with a p-value <0.05) and mixed results on the secondary endpoints including function (ADL), which we believe should be good enough to support a regulatory submission. While aducanumab has a marginally different mechanism of action, we nevertheless expect BIIB shares to trade in sympathy to Lilly.

    Implications for Biogen and Merck: The E3 results are likely to result in volatility for Biogen (up 20-30%, down 10-15%) as Alzheimer’s drives both long-term growth and M&A value even though aducanumab works differently from solanezumab.

    Aducanumab dose titration data is expected at the CTAD meeting (San Diego, Dec. 9). Merck’s Phase 2/3 EPOCH verubecestat (BACE) trial is scheduled to finish in June 2017 but unlike E3, PET scans/CSF tests for A were not an inclusion criteria. We think Merck shares could move 3% to 5% in either direction in sympathy to E3.

    At $76.58, Lillys share price has fallen more than 9% over the past year, while Biogen has climbed more than 9% over the same span.

  • [By David Zeiler]

    Pharma stocks shot up in the wake of Donald Trump’s victory. Eli Lilly and Co. (NYSE: LLY) and Merck & Co. (NYSE: MRK) both rose about 6%, while Pfizer Inc. (NYSE: PFE) jumped 7%.


Advisors’ Opinion:

  • [By Monica Gerson]

    Wall Street expects Science Applications International Corp (NYSE: SAIC) to report its quarterly earnings at $0.74 per share on revenue of $1.15 billion. SAIC shares gained 0.96 percent to $57.87 in after-hours trading.

  • [By Lisa Levin]


    Pyxis Tankers Inc. (NYSE: PXS) rose 47.48 percent to $$5.56, after the company announced it has entered into a definitive securities purchase agreement with a group of investors, which will result in gross proceeds of $4.8 million.
    Sigma Designs Inc (NASDAQ: SIGM) rose 22.77 percent to $6.88. Silicon Laboratories (NASDAQ: SLAB) announced plans to buy Sigma Designs for $7.05 per share in cash.
    Steadymed Ltd (NASDAQ: STDY) rose 19.35 percent to $3.70, after the company reported that no clinical trials were required for Trevyent and that the FDA had agreed to the pathway for the drug candidate's NDA resubmission.
    Iteris, Inc. (NASDAQ: ITI) rose 15.73 percent to $7.06. Earlier in the week, Zacks Investment Research had upgraded the company from "Sell" to "Hold".
    Science Applications International Corp (NYSE: SAIC) rose 13.71 percent to $85.77 as the company reported better-than-expected earnings for its third quarter.
    Technical Communications Corporation (NASDAQ: TCCO) rose 12.41 percent to $6.07, after having risen sharply in pre-marketing trading.
    Radius Health, Inc. (NASDAQ: RDUS) rose 12.41 percent to $30.81 after the company provided an update on data from the Phase 1 005 clinical study of elacestrant in patients with estrogen receptor positive breast cancer during the 2017 San Antonio Breast Cancer Symposium.
    ForeScout Technologies, Inc. (NASDAQ: FSCT) rose 12.32 percent to $25.80 after the company reported its third quarter financial results.
    Prana Biotechnology Limited (NASDAQ: PRAN) rose 11.36 percent to $3.43, as the company announced a research collaboration with Takeda Pharmaceuticals to study the ability of movement disorders compound, PBT434 to slow or prevent neurodegeneration of the gastrointestinal system.
    Catalyst Biosciences, Inc. (NASDAQ: CBIO) rose 10.49 percent to $7.90 as the company announced the appointment of Arwa Shurrab and Jamie Ellen Siegel in its clinical hemophilia

  • [By Monica Gerson]

    Science Applications International Corp (NYSE: SAIC) is estimated to report its quarterly earnings at $0.74 per share on revenue of $1.15 billion.

Top 5 Safest Stocks To Buy Right Now: ChannelAdvisor Corporation(ECOM )

Advisors’ Opinion:

  • [By Lisa Levin]

    ChannelAdvisor Corp (NASDAQ: ECOM) shares dropped 24 percent to $10.85 following Q4 results. ChannelAdvisor reported Q4 net income of $5.8 million on revenue of $31.8 million.

Top 5 Safest Stocks To Buy Right Now: Medtronic plc(MDT)

Advisors’ Opinion:

  • [By James E. Brumley]

    When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.

    General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.

    Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.

    The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.

    Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It

  • [By Keith Fitz-Gerald]

    I’ve long thought that Medtronic (NYSE:MDT) would be a suitable buyer, as was the subject of unconfirmed rumors last month. However, I could also envision a defense contractor moving in simply because so much of the intellectual property could easily crossover to military applications. Or, even Google X for that matter.

  • [By George Budwell, Keith Speights, and Cory Renauer]

    So, to help investors separate the wheat from the chaff, we asked our Foolish contributors which stocks they thought are worth owning until at least 2030. These three healthcare specialists recommended Medtronic (NYSE:MDT), Johnson & Johnson (NYSE:JNJ), andIntuitive Surgical (NASDAQ:ISRG). Read on to find out why.

  • [By Todd Campbell]

    At Medtronic (NYSE:MDT), one of the country’s largest medical-device companies, these sensors are even attached to an insulin pump patients wear that canautomatically administer insulin as it’s needed.

  • [By ]

    Medical device makers will also be in the price-control crosshairs. If the government can mandate drug prices, the same can be expected for pacemakers, artificial joints and other devices. Companies such as Medtronic (NYSE: MDT) and previously mentioned pharma giant Johnson & Johnson will find themselves adjusting to a new paradigm.

Leave a Reply

Your email address will not be published. Required fields are marked *